<DOC>
	<DOCNO>NCT00943319</DOCNO>
	<brief_summary>The purpose study : 1 . To establish maximally tolerate dose ( MTD ) intravenous busulfan ( BusulfanÂ® ) combination fludarabine condition regimen transplantation in-vivo T-cell depletion . 2 . To evaluate disease free overall survival condition regimen patient advance acute myeloid leukemia ( AML ) myelodysplastic syndrome ( MDS ) . 3 . To evaluate potential pharmacogenomic determinant toxicity regimen . 4 . To evaluate potential pharmacogenomic determinant efficacy regimen .</brief_summary>
	<brief_title>Busulfan-fludarabine Conditioning T-cell Depleted Allogeneic Stem Cell Transplantation Patients With Advanced Hematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Phase I portion : Relapsed refractory acute myelogenous lymphoid leukemia . Chronic myelogenous leukemia accelerate phase blastcrisis . Recurrent refractory malignant lymphoma Hodgkin 's disease Recurrent refractory multiple myeloma . Chronic lymphocytic leukemia , relapse poor prognostic feature . Myeloproliferative disorder ( polycythemia vera , myelofibrosis ) transformation Myelodysplastic syndromes 5 % blast . Phase II portion : AML active disease beyond CR2 . MDS 5 % blast . Clinical progression . Such patient may treat treatment protocol investigator 's discretion . Such patient continue monitor survival , may ask continue provide specimens study minimal residual disease immune reconstitution treatment recommend .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Cancers blood</keyword>
</DOC>